Holen Sie sich die Stockscreener-App
19.34
3.15%
0.59
Handel nachbörslich:
19.00
-0.34
-1.76%
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
Form 4 Vor Biopharma Inc For: 5 October By Investing.com - Investing.com Canada
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Vor Biopharma (Nasdaq:VOR)Stock Analysis - Simply Wall Street
Jefferies Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $48 - moomoo.com
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com India
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com Canada
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com UK
VOR: Phase III MG trial enrollment complete; robust efficacy and market expansion plans underway - TradingView
Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Mar - GuruFocus
Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis - marketscreener.com
Vor Biopharma Inc. (VOR) Latest Press Releases & Corporate News - Yahoo Finance
Vor Biopharma (VOR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VOR - MarketBeat
Vor Biopharma Stock Price Forecast. Should You Buy VOR? - StockInvest.us
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - sg.finance.yahoo.com
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Vor Bio To Participate in Upcoming September Conferences - marketscreener.com
Vor Bio To Participate in Upcoming September Conferences - Yahoo Finance
Vor Biopharma Inc. (VOR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vor Biopharma (VOR) RA Capital-linked option yields 1,500 shares - Stock Titan
Why Did Vor Biopharma (VOR) Stock Drop After Its Latest Update? - Sahm
Vor (VOR) Snapshot: Adds 1.28% to Close at $23.36 on the Day; Key Range: Support at $22.19 and Resistance at $24.53 Frame the Range in the Latest ReadingHot Stock Picks - vinanet.vn
US and Canadian markets settled this week on a negative note, Two stocks to consider – LITH, VOR - kalkine.ca
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake - Stock Titan
Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership - Stock Titan
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright - MarketBeat
Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock - Stock Titan
Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18 - webull.com
VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00 - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings - MarketBeat
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma (VOR) Reports Improved Cash Position and Reduced L - GuruFocus
Vor Biopharma Reports Q2 2026 Financial Results in SEC Form 10-Q Filing - Kalkine Media
Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate - scanx.trade
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results - MarketBeat
Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations - GuruFocus
VOR Stock Update: Telitacicept Advances Amid Mixed Financial Sig - GuruFocus
Vor Biopharma Shares Drop After Q2 Results - marketscreener.com
Vor Biopharma Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs - TradingView
4.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):